These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31969412)

  • 1. Follicular lymphoma presenting as hyperleucocytosis.
    Worth HA; Cochrane K; Aljadir D
    BMJ Case Rep; 2020 Jan; 13(1):. PubMed ID: 31969412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.
    Sarkozy C; Baseggio L; Feugier P; Callet-Bauchu E; Karlin L; Seymour JF; Lebras L; Michallet AS; Offner F; Dumas O; Traverse-Glehen A; Ffrench M; Lopez-Guillermo A; Berger F; Coiffier B; Felman P; Salles G
    Br J Haematol; 2014 Mar; 164(5):659-67. PubMed ID: 24274024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
    Keating GM
    Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapy.
    Heger JM; Eichenauer DA; Kasper P; Böll B; Shimabukuro-Vornhagen A; Kochanek M
    Eur J Haematol; 2019 Sep; 103(3):268-271. PubMed ID: 31211882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
    Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
    J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
    Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
    Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Double-Hit Follicular Lymphoma with BCL2 and MYC Translocations].
    Horiuchi M; Fuseya H; Tsutsumi M; Hayashi Y; Hagihara K; Kanashima H; Nakao T; Fukushima Y; Inoue T; Yamane T
    Gan To Kagaku Ryoho; 2016 Sep; 43(9):1135-8. PubMed ID: 27628560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
    Advani R; Flinn I; Popplewell L; Forero A; Bartlett NL; Ghosh N; Kline J; Roschewski M; LaCasce A; Collins GP; Tran T; Lynn J; Chen JY; Volkmer JP; Agoram B; Huang J; Majeti R; Weissman IL; Takimoto CH; Chao MP; Smith SM
    N Engl J Med; 2018 Nov; 379(18):1711-1721. PubMed ID: 30380386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Nomoto J; Miyamoto K; Fukuhara S; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Hum Pathol; 2013 Nov; 44(11):2529-35. PubMed ID: 23916290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report.
    Tsutsumi Y; Ohigashi H; Ito S; Shiratori S; Teshima T
    J Med Case Rep; 2016 Feb; 10():27. PubMed ID: 26838941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of immunohistochemistry with an antibody against MYC at the initial diagnosis of follicular lymphoma, grade 3A, for predicting a more aggressive clinical course: a case report and review of the literature.
    Ichikawa K; Aritaka N; Ogura K; Hosone M; Ota Y; Sato E; Komatsu N; Hirano T
    Int J Clin Exp Pathol; 2015; 8(6):7559-64. PubMed ID: 26261669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular lymphoma: expanding therapeutic options.
    Ganti AK; Bociek RG; Bierman PJ; Enke CA; Vose JM; Armitage JO
    Oncology (Williston Park); 2005 Feb; 19(2):213-28; discussion 228, 233-6, 239. PubMed ID: 15770890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-Hit and Triple-Hit Follicular Lymphoma.
    Ziemba JB; Wolf Z; Weinstock M; Asakrah S
    Am J Clin Pathol; 2020 Apr; 153(5):672-685. PubMed ID: 32112707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
    Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
    Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab.
    Czuczman MS; Grillo-López AJ; Alkuzweny B; Weaver R; Larocca A; McLaughlin P
    Leuk Lymphoma; 2006 Sep; 47(9):1830-40. PubMed ID: 17064996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
    Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
    Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical Burkitt's lymphoma transforming from follicular lymphoma.
    Hwang YY; Loong F; Chung LP; Chim CS
    Diagn Pathol; 2011 Jul; 6():63. PubMed ID: 21736761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
    Găman AM
    Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous regression of chemotherapy-refractory non-Hodgkin's lymphoma preceding the development of secondary leukaemia.
    Grigg AP; Gascoyne RD; Barnett MJ
    Leuk Lymphoma; 1996 Jan; 20(3-4):351-3. PubMed ID: 8624480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature.
    Miao Y; Hu S; Lu X; Li S; Wang W; Medeiros LJ; Lin P
    Hum Pathol; 2016 Dec; 58():72-77. PubMed ID: 27544800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.